{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:51:24Z","timestamp":1784260284348,"version":"3.55.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cld.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:43:05Z","timestamp":1615423385000},"page":"291-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Prevention of First Decompensation in Advanced Chronic Liver Disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Mattias","family":"Mandorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"D'Amico","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.dld.2016.09.013","article-title":"Beta blockers and cirrhosis, 2016","volume":"49","author":"Mandorfer","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhepr.2019.02.006","article-title":"Anticoagulation in the cirrhotic patient","volume":"1","author":"Turco","year":"2019","journal-title":"JHEP Rep"},{"issue":"39","key":"10.1016\/j.cld.2021.01.003_bib10","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.3748\/wjg.v25.i39.5897","article-title":"Gut-liver axis signaling in portal hypertension","volume":"25","author":"Simbrunner","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib12","article-title":"Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis","author":"Komolafe","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","volume":"72","author":"Bajaj","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","article-title":"Albumin in decompensated cirrhosis: new concepts and perspectives","volume":"69","author":"Bernardi","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib15","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.jhepr.2020.100122","article-title":"Where does TIPS fit in the management of patients with cirrhosis?","volume":"2","author":"Garcia-Pagan","year":"2020","journal-title":"JHEP Rep"},{"issue":"15","key":"10.1016\/j.cld.2021.01.003_bib16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension","volume":"51","author":"Manolakopoulos","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"9865","key":"10.1016\/j.cld.2021.01.003_bib18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2021.01.003_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2021.01.003_bib23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2011.03.002","article-title":"Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection","volume":"9","author":"Reiberger","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2021.01.003_bib24","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.cgh.2015.04.013","article-title":"Association between severe portal hypertension and risk of liver decompensation in patients with Hepatitis C, regardless of response to antiviral therapy","volume":"13","author":"Lens","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating Hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2021.01.003_bib26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3851\/IMP2349","article-title":"A\u00a0prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin","volume":"17","author":"Reiberger","year":"2012","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/apt.13315","article-title":"Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses","volume":"42","author":"Mandorfer","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jvh.13232","article-title":"Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis","volume":"27","author":"McDonald","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib31","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2021.01.003_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","author":"Afdhal","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2021.01.003_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa502","article-title":"Persistence of clinically significant portal hypertension after eradication of HCV in patients with advanced cirrhosis","author":"Diez","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2021.01.003_bib36","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide","volume":"17","author":"Shah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/hepr.12131","article-title":"Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: a systematic review and meta-analysis","volume":"44","author":"Xie","year":"2014","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/liv.12242","article-title":"Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease","volume":"34","author":"Masson","year":"2014","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhep.2017.01.018","article-title":"Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis","volume":"67","author":"Atkinson","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib41","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/hep.29825","article-title":"People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol","volume":"67","author":"Atkinson","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib42","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0016-5085(97)70142-2","article-title":"Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis","volume":"112","author":"Luca","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/liv.12559","article-title":"Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure","volume":"35","author":"Mehta","year":"2015","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.cld.2021.01.003_bib45","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MEG.0000000000001148","article-title":"A\u00a0return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis","volume":"30","author":"Spahr","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib46","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study","volume":"111","author":"Vorobioff","year":"1996","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11901-019-00469-x","article-title":"Hepatic venous pressure gradient response in non-selective beta-blocker treatment\u2014is it worth measuring?","volume":"18","author":"Mandorfer","year":"2019","journal-title":"Curr Hepatol Rep"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib48","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0016-5085(90)91168-6","article-title":"Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage","volume":"99","author":"Groszmann","year":"1990","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib49","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2004.01.017","article-title":"Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis","volume":"40","author":"Villanueva","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/hep.25686","article-title":"Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding","volume":"56","author":"Augustin","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib52","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib56","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A\u00a0randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib57","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"issue":"10215","key":"10.1016\/j.cld.2021.01.003_bib60","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib62","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2008.07.019","article-title":"Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment","volume":"135","author":"Huet","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0168-8278(87)80035-1","article-title":"Portal hypertension in primary biliary cirrhosis. Relationship with histological features","volume":"5","author":"Navasa","year":"1987","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2021.01.003_bib64","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2021.01.003_bib66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib67","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib69","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.cld.2021.01.003_bib71","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2021.01.003_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000440827","article-title":"Therapy of primary sclerosing cholangitis--today and tomorrow","volume":"33","author":"Halilbasic","year":"2015","journal-title":"Dig Dis"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib74","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib75","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib76","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2021.01.003_bib77","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease","volume":"45","author":"Schwabl","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.cld.2021.01.003_bib79","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/apt.14522","article-title":"Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity","volume":"47","author":"Mandorfer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2021.01.003_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30733-9","article-title":"Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease","author":"Semmler","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib81","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0040-1708806","article-title":"Noninvasive diagnostics for portal hypertension: a comprehensive review","volume":"40","author":"Mandorfer","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib84","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib85","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2021.01.003_bib86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib87","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2017.12.027","article-title":"Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis","volume":"68","author":"Turco","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.01.003_bib88","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.01.003_bib89","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib90","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2021.01.003_bib91","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.cld.2021.01.003_bib92","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2021.01.003_bib93","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/gutjnl-2016-312814","article-title":"Prevention of progression from small to large varices: are we there yet? An updated meta-analysis","volume":"66","author":"Mandorfer","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib94","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"10181","key":"10.1016\/j.cld.2021.01.003_bib95","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cld.2021.01.003_bib96","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.14576","article-title":"Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study","volume":"47","author":"Schwarzer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2021.01.003_bib97","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.cld.2021.01.003_bib98","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"issue":"12a","key":"10.1016\/j.cld.2021.01.003_bib100","doi-asserted-by":"crossref","first-page":"15e","DOI":"10.1016\/S0002-9149(00)00946-2","article-title":"Defining patient risks from expanded preventive therapies","volume":"85","author":"Tolman","year":"2000","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.cld.2021.01.003_bib101","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib102","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jgh.12657","article-title":"Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study","volume":"30","author":"Chang","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib103","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2021.01.003_bib104","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cld.2021.01.003_bib105","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2021.01.003_bib106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2021.01.003_bib108","unstructured":"Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development (2018-001698-25). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03780673. Accessed February 10, 2021."},{"issue":"9","key":"10.1016\/j.cld.2021.01.003_bib109","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.dld.2020.06.048","article-title":"Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: a systematic review and meta-analysis","volume":"52","author":"Mendoza","year":"2020","journal-title":"Dig Liver Dis"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:57:50Z","timestamp":1761069470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1089326121000039"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.01.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of First Decompensation in Advanced Chronic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}